Canaccord Slashes Price Target for AEterna Zentaris Inc. (USA) Following 4Q:14 Results
Canaccord Genuity analyst Neil Maruoka came out with a research note on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), reducing the price target to $0.70 (from $0.80), and maintaining a Hold rating on the stock. The decreased price target comes after the company released its fourth-quarter results on Tuesday, posting operating loss of $10.9 million.
Maruoka noted, "We value Æterna Zentaris based on a probability-weighted NPV model of its most advanced therapies, using a 15% discount rate and a 45% probability of success for Zoptarelin in endometrial cancer. Following the recent financing, we have included the additional shares, which was partially offset as we rolled our valuation year forward. Based on this analysis, we are lowering our target price to US$0.70, which implies a 28.0% annualized return and continues to support our HOLD rating."
According to TipRanks.com, which measures analysts' and bloggers' success rate based on how their calls perform, analyst Neil Maruoka has a total average return of 15.0% and a 78.9% success rate. Maruoka is ranked #838 out of 3535 analysts.